Close menu




November 6th, 2020 | 11:04 CET

NEL ASA, Velocity Minerals, Barrick Gold - the next chance!

  • Innovations
Photo credits: pixabay.com

The market does what it wants. Anticipating a worst-case scenario, the markets drew a zig-zag ahead of Tuesday’s election but then settled back into a positive momentum. Dax alone made-up almost 700 points after the index plunged below 12,000 on Wednesday. Although the election spectacle is still not over, the stock markets are rising as if there were no tomorrow. On a positive note, gold has held on to its crucial support zone and is marching dynamically towards its all-time high. A breakout should be a matter of time.

time to read: 2 minutes | Author: Stefan Feulner
ISIN: CA92258F3007 , NO0010081235 , CA0679011084

Table of contents:


    Gold mines explode

    Due to the rising gold price, first the gold mines of the first row like Barrick Gold, Iam Gold or Newcrest Mining, profit disproportionately. Should the gold price march consistently above the old highs, the leverage will lie instead with the smaller producers. The Canadian exploration Company, Velocity Minerals, is exciting. The Canadians are focused on the discovery and development of gold deposits in Bulgaria. Bulgaria is the country with the largest gold reserves in Europe. The Company's strategy is to develop a low-cost operation where multiple projects deliver gold concentrates to an existing central processing facility.

    Prospective drilling

    Velocity Minerals' flagship project is its 70% interest in Rozino. A PFS, Pre-Feasibility Study, was released last August. Gold mining production could start in 2022, with an after-tax internal rate of return of 27%, per annum! Yesterday, Velocity announced another milestone. In addition to Rozino, another coup appears to have been achieved on the Obichnik project. Both the two new drill holes tested from Premka Zone yielded high mineralization results.

    Golden Future

    President and CEO of Velocity Minerals commented: "The high-grade nature of the gold mineralization is very encouraging and there is more drilling to do at this target. We remain focused on building a multi-asset gold production profile in Bulgaria with a ‘Hub & Spoke’ development strategy. With the recent positive prefeasibility at the Rozino project, we continue to advance our exploration drill programs for resource expansion and definition at Rozino as well as the Obichnik, Makedontsi and Iglika projects."

    Numbers weak thanks to Nikola

    A successful hydrogen Company is in the red. How is that possible? In the case of the Norwegian showpiece Company, NEL ASA, it is due to the participation in the US truck builder Nikola, which still has to defend itself against massive fraud allegations. The negative market value adjustment of NOK 513.3 resulted in an EBITDA of NOK -42.1 million in the third quarter. Reported EBIT was NOK -116.3 million, while the pre-tax loss was NOK -628.6 million, as described above. In terms of turnover, the Scandinavian companies were able to maintain their turnover at NOK 147.7 million, roughly the same level as the previous year (NOK 148.9 million).

    Bright future

    NEL ASA was only able to show the positive trend in the hydrogen industry in terms of the order backlog. With an order backlog of NOK 940.0 million, the Company topped the previous year's figure by a whopping 60%. The coffers are full to the brim with NOK 2.5 billion, the equivalent of around EUR 230 million, to finance further dynamic growth.

    New prestige order

    Earlier this week, NEL ASA announced a significant order. None other than the Spanish utility giant Iberdrola selected the Norwegians as the preferred supplier for a 20-megawatt green fertilizer project in Spain. According to press reports, the plant is scheduled to go into operation as early as 2021. Iberdrola, one of the world's largest electricity suppliers, wants to build the largest environmentally friendly hydrogen plant in cooperation with fertilizer manufacturer, Fertiberia.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Nico Popp on October 2nd, 2026 | 09:50 CEST

    Formycon and the Patent Cliff: Why Expiring Patents at Novartis and Merck Present an Opportunity for the German Biotech Industry

    • Biotechnology
    • Pharma
    • patents
    • Innovations
    • biosimilars

    Even pharmaceutical giants are coming under pressure. The key term here is the patent cliff. According to industry estimates, between 2025 and 2030, active pharmaceutical ingredients with a global sales volume of approximately USD 300 billion will lose their exclusive patent protection. This turning point is forcing even pharmaceutical giants to rethink their strategies. Specialized developers will then bring biosimilars to market—equivalent and more affordable alternatives for healthcare systems. One well-known biosimilar provider is the German company Formycon. We examine the market and outline what makes Formycon's investment story compelling. But first, we look at two international pharmaceutical companies.

    Read

    Commented by Nico Popp on September 25th, 2026 | 07:50 CEST

    Breakthroughs in Skin Cancer Treatment: New Approaches from Biofrontera and Moderna – Vidac Pharma Faces a Busy Fall

    • Pharma
    • Biotechnology
    • Biotech
    • Cancer
    • Innovations

    For a long time, the treatment of skin cancer and its precancerous stages resembled a makeshift compromise: Doctors used scalpels, froze affected areas, or prescribed aggressive creams that destroyed tissue. It was not uncommon for patients to suffer pain and weeks of delayed wound healing. But a completely new dynamic is currently emerging in the sector. Suddenly, innovations involving light beams, messenger RNA (mRNA), and the metabolic reprogramming of cancer cells are making headlines. We present the latest developments in skin cancer and its precancerous stages. The race for innovation has only just begun.

    Read

    Commented by Nico Popp on September 16th, 2026 | 06:55 CEST

    The End of Weight-Loss Shots? Innovations at Merck and Novo Nordisk—BioNxt Solutions Poised for a Hot Fall?

    • Biotechnology
    • Biotech
    • Innovations
    • Obesity
    • weightloss
    • Health

    The battle against excess weight is no longer merely a lifestyle issue. Medical professionals now view extreme obesity as a chronic disease that weakens the body and can lead to serious cardiovascular conditions, as cardiological studies have shown. By contrast, sustained weight loss can help pave the way to a longer, healthier life. This insight, combined with pharmaceutical innovation, has sparked an unprecedented race to develop weight-loss drugs. Companies are searching for the ideal way to boost metabolism while making medication as easy and convenient to take as possible.

    Read